Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890203421> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2890203421 abstract "TPS11626 Background: Ewing sarcoma (ES) is a rare cancer that affects children and young adults. Patients with recurrent/refractory ES have a poor prognosis (5-year survival 10-15%) with no improvement despite advances in cytotoxic and targeted therapies. Genomic rearrangements resulting in fusion proteins and over-expression of ets family transcription factors occur in 95% of ES. In particular, the EWS-FLI1 oncogenic fusion creates a constitutively active transcription factor that drives the malignant ES phenotype. Strategies to target the EWS-FLI1 fusion protein have been limited by lack of specificity. A promising approach is to target the interaction of the ets transcription factor with its critical protein partner, RNA helicase A (RHA). TK216 is a novel small-molecule that directly binds to EWS-FLI1 and inhibits its function by blocking binding to RHA. TK216 demonstrates potent anti-proliferative effects on ES cell lines and xenografts. Methods: We initiated a Phase 1, first-in-human, open-label, multi-center, dose-escalation/dose-expansion trial of TK216 in patients with recurrent/refractory ES who are ≥12 years of age (ClinicalTrials.gov: NCT02657005). TK216 is dosed based on body surface area and administered as a continuous intravenous infusion for 7 days followed by 14 days rest every 21 days. Treatment may continue in the absence of disease progression. One intrapatient dose escalation is allowed. Enrollment of 6 to 8 cohorts using a 3+3 dose-escalation design is anticipated. During dose expansion, a total of 18 patients with ES will be accrued at the recommended Phase 2 dose (RP2D). The primary objective of the study is to determine the maximum tolerated dose and RP2D of TK216. Secondary objectives are to assess the safety profile, pharmacokinetics, pharmacodynamics, and antitumor activity of TK216. Molecular assays will be performed to characterize EWS-FLI or EWS-ets abnormalities in archival tumor tissue. The overall response rate, duration of response, progression-free survival, and overall survival will be determined in the expansion cohort. Nine patients have been enrolled since June 2016. Accrual to cohorts 1, 2, and 3 completed and cohort 4 opened in January 2017. Clinical trial information: NCT02657005." @default.
- W2890203421 created "2018-09-27" @default.
- W2890203421 creator A5005083505 @default.
- W2890203421 creator A5010913859 @default.
- W2890203421 creator A5032323384 @default.
- W2890203421 creator A5043007782 @default.
- W2890203421 creator A5048956714 @default.
- W2890203421 creator A5053545098 @default.
- W2890203421 creator A5065709859 @default.
- W2890203421 creator A5066010864 @default.
- W2890203421 creator A5077578026 @default.
- W2890203421 creator A5083229382 @default.
- W2890203421 creator A5090167515 @default.
- W2890203421 creator A5090754657 @default.
- W2890203421 date "2017-05-20" @default.
- W2890203421 modified "2023-09-23" @default.
- W2890203421 title "A phase I, first-in-human, dose escalation study of intravenous TK216 in patients with relapsed or refractory Ewing sarcoma." @default.
- W2890203421 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.tps11626" @default.
- W2890203421 hasPublicationYear "2017" @default.
- W2890203421 type Work @default.
- W2890203421 sameAs 2890203421 @default.
- W2890203421 citedByCount "5" @default.
- W2890203421 countsByYear W28902034212019 @default.
- W2890203421 countsByYear W28902034212020 @default.
- W2890203421 crossrefType "journal-article" @default.
- W2890203421 hasAuthorship W2890203421A5005083505 @default.
- W2890203421 hasAuthorship W2890203421A5010913859 @default.
- W2890203421 hasAuthorship W2890203421A5032323384 @default.
- W2890203421 hasAuthorship W2890203421A5043007782 @default.
- W2890203421 hasAuthorship W2890203421A5048956714 @default.
- W2890203421 hasAuthorship W2890203421A5053545098 @default.
- W2890203421 hasAuthorship W2890203421A5065709859 @default.
- W2890203421 hasAuthorship W2890203421A5066010864 @default.
- W2890203421 hasAuthorship W2890203421A5077578026 @default.
- W2890203421 hasAuthorship W2890203421A5083229382 @default.
- W2890203421 hasAuthorship W2890203421A5090167515 @default.
- W2890203421 hasAuthorship W2890203421A5090754657 @default.
- W2890203421 hasConcept C121332964 @default.
- W2890203421 hasConcept C126322002 @default.
- W2890203421 hasConcept C142424586 @default.
- W2890203421 hasConcept C142724271 @default.
- W2890203421 hasConcept C143998085 @default.
- W2890203421 hasConcept C2776056953 @default.
- W2890203421 hasConcept C2777586341 @default.
- W2890203421 hasConcept C2778256501 @default.
- W2890203421 hasConcept C71924100 @default.
- W2890203421 hasConcept C87355193 @default.
- W2890203421 hasConceptScore W2890203421C121332964 @default.
- W2890203421 hasConceptScore W2890203421C126322002 @default.
- W2890203421 hasConceptScore W2890203421C142424586 @default.
- W2890203421 hasConceptScore W2890203421C142724271 @default.
- W2890203421 hasConceptScore W2890203421C143998085 @default.
- W2890203421 hasConceptScore W2890203421C2776056953 @default.
- W2890203421 hasConceptScore W2890203421C2777586341 @default.
- W2890203421 hasConceptScore W2890203421C2778256501 @default.
- W2890203421 hasConceptScore W2890203421C71924100 @default.
- W2890203421 hasConceptScore W2890203421C87355193 @default.
- W2890203421 hasLocation W28902034211 @default.
- W2890203421 hasOpenAccess W2890203421 @default.
- W2890203421 hasPrimaryLocation W28902034211 @default.
- W2890203421 hasRelatedWork W1997722571 @default.
- W2890203421 hasRelatedWork W2009123941 @default.
- W2890203421 hasRelatedWork W2036082666 @default.
- W2890203421 hasRelatedWork W2056457940 @default.
- W2890203421 hasRelatedWork W2060090209 @default.
- W2890203421 hasRelatedWork W2107172831 @default.
- W2890203421 hasRelatedWork W2180221890 @default.
- W2890203421 hasRelatedWork W2218526370 @default.
- W2890203421 hasRelatedWork W2262833453 @default.
- W2890203421 hasRelatedWork W2293749718 @default.
- W2890203421 hasRelatedWork W2321233371 @default.
- W2890203421 hasRelatedWork W2417485617 @default.
- W2890203421 hasRelatedWork W2420845136 @default.
- W2890203421 hasRelatedWork W2801746568 @default.
- W2890203421 hasRelatedWork W2959735513 @default.
- W2890203421 hasRelatedWork W3013031731 @default.
- W2890203421 hasRelatedWork W3032491121 @default.
- W2890203421 hasRelatedWork W3044911430 @default.
- W2890203421 hasRelatedWork W3169741181 @default.
- W2890203421 hasRelatedWork W2340465321 @default.
- W2890203421 isParatext "false" @default.
- W2890203421 isRetracted "false" @default.
- W2890203421 magId "2890203421" @default.
- W2890203421 workType "article" @default.